Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
08 déc. 2022 16h01 HE
|
Autolus Therapeutics plc
Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)Encouraging safety data observed,...
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
30 nov. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
03 nov. 2022 09h31 HE
|
Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
03 nov. 2022 07h00 HE
|
Autolus Therapeutics plc
Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 updateCommercial manufacturing site build on schedule for handover...
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
21 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Moderna exercises option to license proprietary targeting technology from Autolus
12 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
04 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
04 août 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 07h54 HE
|
Autolus Therapeutics plc
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON,...
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...